Additionally, a webcast replay of the conference call will be available on the Investors section of the Company’s website following the call. Dentsply Sirona is the world’s largest diversified ...

Management reaffirmed the full-year 2025 guidance for organic sales to decline by 2%-4% and adjusted EPS to remain in the range of $1.80 to $2. Reported sales guidance was revised upward to $3.6 ...

XRAY, is contending with declining revenue and negative return on invested capital, pointing to ongoing business and execution challenges. These issues raise questions about competitive pressures in ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

DENTSPLY SIRONA (XRAY) is back in focus after softer quarterly results, ongoing constant currency revenue declines over the past two years, and weaker return on invested capital raised fresh questions ...

Dentsply Sirona Inc. (NASDAQ:XRAY) stock surged about 15% Thursday, and was on track for the biggest single-day advance since 2019 after posting earnings that topped estimates. The company reported ...

Sirona is not beating around the bush: the company has had a difficult time selling its diabetes med and is now “less confident” it will score a licensing deal. The candid about-face came in a ...

(Reuters) - Dentsply International Inc said on Tuesday it would buy peer Sirona Dental Systems Inc in a $5.56 billion all-stock deal, creating the world's largest dental equipment maker. Sirona ...

Wanbang Biopharmaceuticals is expanding a years-long partnership with Canadian biotech Sirona Biochem for global licensing rights to an investigational non-insulin diabetes treatment in both people ...